Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

Status Completed

Clinical Trial Summary

Conducted as a randomized controlled clinical trial, this study aims to assess the potential benefits of incorporating dapagliflozin, an SGLT-2 inhibitor, into the treatment regimen of patients diagnosed with primary nephrotic syndrome. The primary focus is on examining the impact of dapagliflozin on two key parameters: proteinuria and estimated glomerular filtration rate (eGFR). The trial involves adult participants who have been definitively diagnosed with primary nephrotic syndrome through renal biopsy. In conjunction with their standard care, these participants will receive a daily dose of dapagliflozin at 10 mg. Over a span of six months, they will undergo comprehensive monthly assessments. These assessments will involve the collection and analysis of urine samples to quantify proteinuria and perform urinalysis. Additionally, blood samples will be taken to determine the estimated eGFR, lipid profile, glycated hemoglobin. Participants will also be encouraged to report any potential side effects resulting from their medication intake.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Nephrosis
Nephrotic Syndrome
Sodium-Glucose Transporter 2 Inhibitors
Syndrome

Clinical Trial Details

NCT number	NCT06026787
Study type	Interventional
Source	Ain Shams University
Contact
Status	Completed
Phase	Phase 4
Start date	August 1, 2022
Completion date	August 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02238418` - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.	Phase 4
Completed	`NCT01895894` - Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome	Phase 4
Completed	`NCT01411982` - Role of PACAP in Nehprotic Syndrome	N/A
Recruiting	`NCT00308321` - Long Term Tapering or Standard Steroids for Nephrotic Syndrome	Phase 4
Active, not recruiting	`NCT03326037` - Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Completed	`NCT01252901` - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases	N/A
Completed	`NCT01197040` - Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome	Phase 3
Terminated	`NCT00883636` - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis	N/A
Completed	`NCT00035334` - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis	Phase 2/Phase 3
Terminated	`NCT00004466` - Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome	Phase 2
Terminated	`NCT04558892` - Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.	Phase 2/Phase 3
Completed	`NCT02257697` - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome	Phase 3
Completed	`NCT00362531` - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome	Phase 2/Phase 3
Completed	`NCT00289328` - Glucocorticoid-induced Osteopenia in Children	N/A
Recruiting	`NCT04759274` - Diuretic Tuner Clinical Decision Support	N/A
Completed	`NCT00001212` - Drug Therapy in Lupus Nephropathy	Phase 2
Recruiting	`NCT05623033` - The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
Completed	`NCT03332420` - The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Not yet recruiting	`NCT05904197` - Effectiveness of Educational Gamified Cards About Nephrotic Syndrome	N/A